Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients

Kwakman, J. J. M.; Kwakman, R. J.; Baars, A.; Boot, H.; Pruijt, J. F. M.; Pruijt, H.; Winther, S. B.; Pfeiffer, P.; Punt, C. J. A.

Published in

Taylor and Francis Group, Acta Oncologica, 7(56), p. 1023-1026, 2017

DOI: 10.1080/0284186x.2016.1278459

Elsevier, European Journal of Cancer, (72), p. S69

DOI: 10.1016/s0959-8049(17)30304-0

Tools

Export citation

Search in Google Scholar

Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients

Journal article published in 2017 by J. J. M. Kwakman, R. J. Kwakman, A. Baars, H. Boot, J. F. M. Pruijt, H. Pruijt, S. B. Winther, P. Pfeiffer, C. J. A. Punt

This paper is available in a repository.

Full text: Download

Preprint: archiving forbidden

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Abstract

Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients

Published in

Links

Tools

Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients

Abstract